Publisher
Springer Science and Business Media LLC
Reference11 articles.
1. Bundesärztekammer. Leitfaden der Arzneimittelkommission der deutschen Ärzteschaft (AkdÄ). Medikamentöse Cholesterinsenkung zur Vorbeugung kardiovaskulärer Ereignisse. 1. Auflage, Version 2.0 Juli 2023. https://www.akdae.de/arzneimitteltherapie/lf/leitfaden-cholesterinsenkung, letzter Zugriff am 8. Jan. 2024
2. LO-DESTAR investigators, Hong SJ, Lee YJ, Lee SJ et al (2023) Treat-to-target oder high-intensity statin in patients with coronary artery disease. JAMA 329:1078–1087. https://doi.org/10.1001/jama.2023.2487
3. Hagiwara N, Kawada-Watanabe E, Koyanagi R et al (2017) Low density lipoprotein cholesterol targeting with pitavastatin + ezetimibe for patients with acute coronary syndrome and dyslipidaemia: the HIJ-PROPER study, a prospective, open-label, randomized trial. Eur Heart J 38:2264–2276. https://doi.org/10.1093/eurheartj/ehx162
4. Itoh H, Komuro I, Takeuchi M et al (2018) Intensive treat-to-target statin therapy in high-risk japanese patients with hypercholesterolemia and diabetic retinopathy: report of a randomized study. Diabetes Care 41:1275–1284. https://doi.org/10.2337/dc17-2224
5. Amarenco P, Kim JS, Labreuche J et al (2020) A comparison of two LDL cholesterol targets after ischemic stroke. N Engl J Med 382:9. https://doi.org/10.1056/NEJMoa1910355